Vaccines
This year's updated Covid-19 vaccines have been approved by the US Food and Drug Administration for adults 65 and older, as well as younger people with certain medical conditions that put them at higher risk of severe Covid-19 infection. The narrower approval may limit access to shots for
Vaccines
U.S. regulators have approved updated COVID-19 shots from Pfizer, Moderna, and Novavax, but with significant restrictions on their use, particularly for younger adults and children. The new shots, which target a newer version of the continuously evolving virus, are approved for all seniors but only for those with at
COVID-19
The Food and Drug Administration (FDA) has approved updated COVID-19 vaccines for the 2025-2026 respiratory disease season, but with significant limitations. According to a post by HHS Secretary Robert F. Kennedy Jr. on X, the updated shots made by Moderna, Pfizer, and Novavax are approved for individuals aged 65 years
COVID-19
The FDA's recent approval of COVID-19 vaccines has come with restrictions on who can receive them, leaving many consumers, healthcare providers, and industry leaders uncertain about the accessibility and effectiveness of these vaccines. The changes have sparked confusion among consumers about the availability of vaccines, the required prescriptions,
COVID-19
Pharmaceutical giants Pfizer Inc and BioNTech SE have secured approval from the US Food & Drug Administration for their COVID-19 vaccine, Comirnaty. The vaccine is designed for use in adults aged 65 and over, as well as individuals aged between 5 and 64 with underlying conditions that put them at
COVID-19
The FDA has granted approval for updated mRNA COVID-19 vaccines from Pfizer and Moderna, but with significant restrictions on their use. Unlike previous endorsements, the new vaccines are only approved for people with underlying health conditions, excluding those without them, regardless of age. The vaccines target the LP.8.1
COVID-19
The US Food and Drug Administration has approved updated Covid-19 vaccines for adults 65 and older, as well as younger individuals who are at higher risk from Covid-19. However, the approvals come with significant restrictions that limit access to these vaccines for younger, healthier individuals. The updated vaccines target coronavirus
Vaccines
The U.S. Food and Drug Administration (FDA) has suspended the biologics license for the live-attenuated chikungunya vaccine, Ixchiq, in response to reports of serious side effects in older adults. The FDA granted accelerated approval of Ixchiq in November 2023 to prevent chikungunya virus in adults 18 years and older
AIDS treatment
The Global Fund to Fight AIDS, Tuberculosis and Malaria has signed an access agreement with Gilead Sciences to procure lenacapavir, a long-acting injectable HIV prevention medication, for low- and middle-income countries. This groundbreaking deal will make lenacapavir available in these countries at the same time as in high-income countries, a
Diseases
Eli Lilly and Company has announced that the US Food and Drug Administration (FDA) has approved a label update for Kisunla (donanemab-azbt), a once-monthly amyloid-targeting therapy for adults with early symptomatic Alzheimer's disease. The updated label includes a new recommended titration dosing schedule, which has been shown to
Diseases
The U.S. Food and Drug Administration (FDA) has approved Insightec's Exablate Neuro platform for staged bilateral pallidothalamic tractotomy treatment in patients living with advanced Parkinson's disease. This new therapeutic option offers a lower risk profile compared to traditional surgical interventions and is incisionless, requiring no
Diseases
KalVista Pharmaceuticals has overcome regulatory hurdles to secure FDA approval for its plasma kallikrein inhibitor sebetralstat, now commercially known as Ekterly. The oral treatment has been approved for managing acute attacks of hereditary angioedema (HAE) in adults and children aged 12 and above. This breakthrough comes after the FDA initially
